Education
About Us
Working with TipRanks
Follow Us
Jupiter Neurosciences, Inc. (JUNS)
NASDAQ:JUNS
JUNS Stock Chart & Stats
$1.10
<$0.01(0.12%)
At close: 4:00 PM EST
$1.10
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$0.51 - $12.81
Previous CloseN/A
Volume197.86K
Average Volume (3M)148.03K
Market Cap
$37.87M
Enterprise ValueN/A
Total Cash (Recent Filing)$723.80K
Total Debt (Recent Filing)$180.39K
Price to Earnings (P/E)―
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding34,426,353
10 Day Avg. Volume107,563
30 Day Avg. Volume148,028
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)73.82
Price to Sales (P/S)0.00
P/FCF Ratio-78.75
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$25.00Price Target Upside2172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jupiter Neurosciences, Inc. News
JUNS FAQ
What was Jupiter Neurosciences, Inc.’s price range in the past 12 months?
Jupiter Neurosciences, Inc. lowest stock price was $0.51 and its highest was $12.81 in the past 12 months.
What is Jupiter Neurosciences, Inc.’s market cap?
Jupiter Neurosciences, Inc.’s market cap is $37.87M.
When is Jupiter Neurosciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jupiter Neurosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Jupiter Neurosciences, Inc. overvalued?
According to Wall Street analysts Jupiter Neurosciences, Inc.’s price is currently Undervalued.
Does Jupiter Neurosciences, Inc. pay dividends?
Jupiter Neurosciences, Inc. does not currently pay dividends.
What is Jupiter Neurosciences, Inc.’s EPS estimate?
Jupiter Neurosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jupiter Neurosciences, Inc. have?
Jupiter Neurosciences, Inc. has 34,426,353 shares outstanding.
What happened to Jupiter Neurosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jupiter Neurosciences, Inc.?
Currently, no hedge funds are holding shares in JUNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jupiter Neurosciences, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (2172.73% Upside)
$25.00 (2172.73% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1773.95%
Trailing 12-Months
Company Description
Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
JUNS Stock 12 Month Forecast
Average Price Target
$25.00
▲(2172.73% Upside)
Technical Analysis
Relmada Therapeutics
―
Gain Therapeutics
―
MiNK Therapeutics
―
Adlai Nortye Ltd. Sponsored ADR
―
OS Therapies Incorporated
―
Ownership Overview
32.76% Insiders
0.42% Mutual Funds
2.82% Other Institutional Investors
63.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---